Akebia Therapeutics (AKBA) Free Cash Flow (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Free Cash Flow data on file, last reported at -$22.0 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 61.38% year-over-year to -$22.0 million in Q1 2026; TTM through Mar 2026 was $57.0 million, a 269.71% increase from a year earlier, with the FY2025 full-year figure at $65.4 million, up 263.27% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$22.0 million, down from $28.7 million in the prior quarter.
• Over the last five years, Free Cash Flow for AKBA reached as high as $28.7 million in Q4 2025 and fell as low as -$54.7 million in Q4 2022.
• Historically, Free Cash Flow has averaged -$5.5 million across 5 years, with a median of -$9.0 million in 2024.
• Across the five-year window, Free Cash Flow slumped 239.75% in 2024 and soared 853.42% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$54.7 million in 2022, then surged by 110.73% to $5.9 million in 2023, then plunged by 164.99% to -$3.8 million in 2024, then surged by 853.42% to $28.7 million in 2025, then plunged by 176.43% to -$22.0 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$22.0 million in Q1 2026, $28.7 million in Q4 2025, and $28.0 million in Q3 2025.